Publication
A Multi-Component Prime-Boost Vaccination Regimen with a Consensus MOMP Antigen Enhances Chlamydia trachomatis Clearance
| dc.contributor.author | Badamchi-Zadeh, Alexander | |
| dc.contributor.author | McKay, Paul F. | |
| dc.contributor.author | Korber, Bette T. | |
| dc.contributor.author | Barinaga, Guillermo | |
| dc.contributor.author | Walters, Adam A. | |
| dc.contributor.author | Nunes, Alexandra | |
| dc.contributor.author | Gomes, João Paulo | |
| dc.contributor.author | Follmann, Frank | |
| dc.contributor.author | Tregoning, John S. | |
| dc.contributor.author | Shattock, Robin J. | |
| dc.date.accessioned | 2017-02-15T16:02:11Z | |
| dc.date.available | 2017-02-15T16:02:11Z | |
| dc.date.issued | 2016-04-28 | |
| dc.description | The Supplementary Material for this article can be found online at http://journal.frontiersin.org/article/10.3389/fimmu.2016.00162 | pt_PT |
| dc.description.abstract | BACKGROUND: A vaccine for Chlamydia trachomatis is of urgent medical need. We explored bioinformatic approaches to generate an immunogen against C. trachomatis that would induce cross-serovar T-cell responses as (i) CD4(+) T cells have been shown in animal models and human studies to be important in chlamydial protection and (ii) antibody responses may be restrictive and serovar specific. METHODS: A consensus antigen based on over 1,500 major outer membrane protein (MOMP) sequences provided high epitope coverage against the most prevalent C. trachomatis strains in silico. Having designed the T-cell immunogen, we assessed it for immunogenicity in prime-boost regimens. This consensus MOMP transgene was delivered using plasmid DNA, Human Adenovirus 5 (HuAd5) or modified vaccinia Ankara (MVA) vectors with or without MF59(®) adjuvanted recombinant MOMP protein. RESULTS: Different regimens induced distinct immune profiles. The DNA-HuAd5-MVA-Protein vaccine regimen induced a cellular response with a Th1-biased serum antibody response, alongside high serum and vaginal MOMP-specific antibodies. This regimen significantly enhanced clearance against intravaginal C. trachomatis serovar D infection in both BALB/c and B6C3F1 mouse strains. This enhanced clearance was shown to be CD4(+) T-cell dependent. Future studies will need to confirm the specificity and precise mechanisms of protection. CONCLUSION: A C. trachomatis vaccine needs to induce a robust cellular response with broad cross-serovar coverage and a heterologous prime-boost regimen may be an approach to achieve this. | pt_PT |
| dc.description.sponsorship | AB was funded by the Wellcome Trust. RS was supported by the European Community’s European 7th Framework Program ADITEC (HEALTH-F4-2011-18 280873). | pt_PT |
| dc.description.version | info:eu-repo/semantics/publishedVersion | pt_PT |
| dc.identifier.citation | Front Immunol. 2016 Apr 28;7:162. doi: 10.3389/fimmu.2016.00162. eCollection 2016 | pt_PT |
| dc.identifier.doi | 10.3389/fimmu.2016.00162 | pt_PT |
| dc.identifier.issn | 1664-3224 | |
| dc.identifier.uri | http://hdl.handle.net/10400.18/4184 | |
| dc.language.iso | eng | pt_PT |
| dc.peerreviewed | yes | pt_PT |
| dc.relation | Advanced Immunization Technologies | |
| dc.relation.publisherversion | http://journal.frontiersin.org/article/10.3389/fimmu.2016.00162/full | pt_PT |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc/4.0/ | pt_PT |
| dc.subject | Chlamydia Trachomatis | pt_PT |
| dc.subject | Vaccine | pt_PT |
| dc.subject | DNA Vaccines | pt_PT |
| dc.subject | Adenovirus-vector Vaccines | pt_PT |
| dc.subject | Consensus | pt_PT |
| dc.subject | Mosaic | pt_PT |
| dc.subject | Prime-boost Regimens | pt_PT |
| dc.subject | Infecções Sexualmente Transmissíveis | pt_PT |
| dc.title | A Multi-Component Prime-Boost Vaccination Regimen with a Consensus MOMP Antigen Enhances Chlamydia trachomatis Clearance | pt_PT |
| dc.type | journal article | |
| dspace.entity.type | Publication | |
| oaire.awardTitle | Advanced Immunization Technologies | |
| oaire.awardURI | info:eu-repo/grantAgreement/EC/FP7/280873/EU | |
| oaire.citation.startPage | 162 | pt_PT |
| oaire.citation.title | Frontiers in Immunology | pt_PT |
| oaire.citation.volume | 7 | pt_PT |
| oaire.fundingStream | FP7 | |
| project.funder.identifier | http://doi.org/10.13039/501100008530 | |
| project.funder.name | European Commission | |
| rcaap.rights | openAccess | pt_PT |
| rcaap.type | article | pt_PT |
| relation.isProjectOfPublication | 0f1935ef-5d43-4ef2-804f-ea502473fea4 | |
| relation.isProjectOfPublication.latestForDiscovery | 0f1935ef-5d43-4ef2-804f-ea502473fea4 |